Skip to main content
Figure 4 | Cardiovascular Diabetology

Figure 4

From: Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

Figure 4

Individual levels of A) low-density lipoprotein cholesterol, B) apolipoprotein B, C) very low-density lipoprotein cholesterol, and D) apolipoprotein C-III in monkeys given aleglitazar 0.03 mg/kg per day. The final day of dosing at 0.03 mg/kg per day aleglitazar (labeled in the figures as day 42), due to scheduling needs, ranged across monkeys from 44 to 46 days.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840